Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials

서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

S-Space

Publications

Detailed Information

Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials

Cited 0 time in Web of Science Cited 0 time in Scopus

Authors: Huber, R.; Gettinger, S.; Kim, D. -W; Bazhenova, L.; Hansen, K.; Tiseo, M.; Langer, C.; Paz-Ares Rodriguez, L.; West, H.; Reckamp, K.; Weiss, G.; Smit, E.; Hochmair, M.; Kim, S. -W; Ahn, M. -J; Kim, E.; Groen, H.; Pye, J.; Vranceanu, F.; Camidge, D. R.

Appears in Collections:

Show Full Item Record

Find it @ SNU

SNS Share